Coronary/Structural Heart

HT Supreme® Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication

TIANJIN, China, Oct. 27, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, announced that the clinical trial results for its HT Supreme® Drug-Eluting Stent (DES) System has been published in Circulation.  The article described results from the PIONEER III trial where investigators demonstrated equivalence in safety and effectiveness between the […]

Encouraging outcomes observed in Europe for the TriGUARD 3™ Cerebral Embolic Protection Device During Transcatheter Heart Procedures

TAMPA, Fla., Oct. 27, 2021 /PRNewswire/ — Keystone Heart Ltd., a Venus Medtech Company, today announced a key milestone in Europe with the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. The device was granted CE mark in March of 2020 and, since launch, utilized in fourteen countries with zero physician-reported strokes. The TriGUARD 3 CEP device is the only […]

One Drop Delivers Novel AI-Powered Solution For Cardiovascular Disease Prevention

Market availability of the cardiovascular disease prevention module co-developed with Bayer demonstrates One Drop’s continued expansion into new therapeutic areas NEW YORK, Oct. 27, 2021 /PRNewswire/ — One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced the release of a digital, AI-enabled cardiovascular disease […]

Teleflex Completes Enrollment in Cardiac IDE Study

Study Evaluates Effectiveness of QuikClot Control+® Hemostatic Device in Patients Undergoing Cardiac Surgery WAYNE, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of the QuikClot Control+® Hemostatic Device […]

The American Society for Preventive Cardiology Publishes Clinical Practice Statement on Improving the Enrollment of Women and Racially/Ethnically Diverse Populations in Cardiovascular Clinical Trials

JACKSONVILLE, Fla., Oct. 26, 2021 /PRNewswire/ — The American Society for Preventive Cardiology (ASPC) has recently published a Clinical Practice Statement in the American Journal of Preventive Cardiology: Improving the Enrollment of Women and Racially/Ethnically Diverse Populations in Cardiovascular Clinical Trials. An ASPC working group was formed, chaired by Dr. Erin Michos and Dr. Keith […]

Coreline AI Coronary Artery Calcium Solution Shows 99.2% Accuracy From a Population Study

SEOUL, South Korea–(BUSINESS WIRE)–Coreline Soft, the developer of the AI Coronary Artery Calcium (CAC) solution named AVIEW CAC, announced that its AI CAC solution showed 99.2% accuracy from a population study conducted by the Institute for Diagnostic Accuracy (iDNA), the NELSON trial team in Europe. The study verified the performance of […]

VenoStent Embarks on Clinical Trial to Improve Success Rate of Vascular Surgery Outcomes

Successful enrollment in initial feasibility trial to support future regulatory submissions and provide better outcomes for patients with end-stage renal disease HOUSTON–(BUSINESS WIRE)–VenoStent, Inc., a clinical-stage tissue engineering company developing tunable, bioabsorbable, smart polymer wraps to fundamentally transform the efficacy of the five million vascular surgeries performed each year, announces […]

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the United States Patent and Trademark […]

Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure

STOCKHOLM SWEDEN – October 25, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its organization in preparation for the initiation of a phase 1b/2a study of its drug candidate AC01 in patients with heart failure. The company’s goal is to develop an […]